Enterprise Value to EBITDA Ratio: Curis Corp (CRIS)
The business foundation of Curis, Inc. (CRIS) is a stable staff of tumor cell researchers and the development of a proprietary targeted therapy system that creates a closed patent portfolio. The linear price action on the GURU.Markets platform chart for the EV/EBITDA metric is 0.00, linking human capital to assets. Curis, Inc. (CRIS) is currently funded by grants while awaiting profits from the market launch of cancer growth blocking drugs.
Summary analytical data breakdowns for curis.com (CRIS)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
CRIS - Net Financial Result|Future Profit Curis, Inc.|CRIS - Company Value to Net Income|Forward P/E Multiple Curis|CRIS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Curis, Inc.|CRIS - Operating profit before amortization|Net earnings per share (EPS TTM) Curis|CRIS - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months curis.com|CRIS - Expected net earnings per share growth this year|Earnings growth forecast for next year Curis, Inc.
Fundamental company analysis:CRIS (Curis Corp)
For the highly scalable intellectual asset business of Curis, Inc. (CRIS), the EV/EBITDA multiple serves as a tool for the real-time monitoring of market value and net debt relative to earnings. The dynamics of this ratio allow investors to instantly differentiate fundamental undervaluation from a liquidity crisis by assessing the efficiency of capitalizing the company's future monopoly advantages during the industrial production of drugs.
Key competitors
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple ERAS|Enterprise Value to EBITDA Ratio delcath.com DCTH|Y-mAbs Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Aura Biosciences Inc AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation ARAY (Accuray, Inc.)|SLS: EV/EBITDA Multiple|ACTU - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Citius Oncology|TuHURA (HURA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio TARA (Protara)|FATE (Fate Pharma) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple WHWK (Aadi Bioscience)|Total Company Value to Operating Income Before Depreciation Ratio TScan Therapeutics Inc (TCRX)|CSBR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XBIT (XBiotech Inc.) - Enterprise Value to Operating Income Before Depreciation|CVM: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio OS Therapies, Inc.|Enterprise Value to EBITDA Ratio RADX|Artiva (ARTV) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ANL|Enterprise Value to EBITDA Ratio Veru Inc VERU|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempest Tx TPST|Business Value to Operating Income Before Depreciation XLO|Enochian BioSciences - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Mural Oncology plc MURA|kairospharma.com (KAPA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OKUR - Total Company Value to Operating Income Before Depreciation Ratio|GDTC (CytoMed Therapeutics Ltd) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Apollomics Corp (APLM)|EV/EBITDA Multiple THAR|EV/EBITDA Multiple advanbiomed.com (ADVB)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Genprex GNPX|CLDI: Enterprise Value to Operating Income Before Depreciation|Sunshine Biopharma - EV/EBITDA Multiple|Xenetic Biosciences (XBIO) - Enterprise Value to EBITDA Ratio|SLRX: EV/EBITDA Multiple|Company Value to EBITDA purple-biotech.com (PPBT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization American Oncology Network Inc|BGNE: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio CKPT (Checkpoint Therapeutics, Inc)|ELEV (Elevation Oncology Inc.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ICAD (iCAD)|IKNA - Enterprise Value to EBITDA Ratio|NTBL: Enterprise Value to EBITDA Ratio|VIRX - EV/EBITDA Multiple|MorphoSys Corp (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NAYA Biosciences Corp - Business Value to Operating Income Before Depreciation|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
